Genmab A/S
Genmab A/S (GNMSF) Financial Performance & Income Statement Overview
Analyze Genmab A/S (GNMSF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Genmab A/S (GNMSF) Income Statement & Financial Overview
Review Genmab A/S GNMSF income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $4.93B | $6.44B | $5.54B | $5.40B |
| Cost of Revenue | $42.00M | $337.00M | $273.00M | $190.00M |
| Gross Profit | $4.77B | $6.10B | $5.27B | $5.21B |
| Gross Profit Ratio | $0.97 | $0.95 | $0.95 | $0.96 |
| R&D Expenses | $359.00M | $2.66B | $2.28B | $2.50B |
| SG&A Expenses | $126.00M | $1.25B | $865.00M | $894.00M |
| Operating Expenses | $485.00M | $3.94B | $3.17B | $3.40B |
| Total Costs & Expenses | $3.64B | $4.28B | $3.44B | $3.76B |
| Interest Income | $233.90M | $224.00M | $162.00M | $292.00M |
| Interest Expense | $35.44M | $54.00M | $18.00M | $19.00M |
| Depreciation & Amortization | $16.00M | $115.00M | $112.00M | $69.00M |
| EBITDA | $265.00M | $2.35B | $1.85B | $2.32B |
| EBITDA Ratio | $0.05 | $0.37 | $0.33 | $0.43 |
| Operating Income | $1.30B | $2.16B | $2.10B | $1.64B |
| Operating Income Ratio | $0.26 | $0.34 | $0.38 | $0.30 |
| Other Income/Expenses (Net) | $56.00M | $1.44B | -$383.00M | $487.00M |
| Income Before Tax | $244.00M | $3.60B | $1.72B | $2.13B |
| Income Before Tax Ratio | $0.05 | $0.56 | $0.31 | $0.39 |
| Income Tax Expense | $49.00M | -$243.00M | $453.00M | $719.00M |
| Net Income | $195.00M | $3.85B | $1.27B | $1.41B |
| Net Income Ratio | $0.04 | $0.60 | $0.23 | $0.26 |
| EPS | $3.06 | $60.51 | $19.94 | $21.85 |
| Diluted EPS | $3.05 | $59.93 | $19.81 | $21.70 |
| Weighted Avg Shares Outstanding | $63.73M | $63.95M | $63.49M | $64.44M |
| Weighted Avg Shares Outstanding (Diluted) | $63.93M | $63.95M | $63.91M | $64.89M |
Over the past four quarters, Genmab A/S demonstrated steady revenue growth, increasing from $5.40B in Q2 2024 to $4.93B in Q1 2025. Operating income reached $1.30B in Q1 2025, maintaining a consistent 26% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $265.00M, reflecting operational efficiency. Net income dropped to $195.00M, with EPS at $3.06. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan